Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab [Immunotherapy]

Conclusion
Atypical responses were observed in patients with melanoma treated with pembrolizumab. Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment.

Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Hodi, Hwu, Kefford, Weber, Daud, Hamid, Patnaik, Ribas, Robert, Gangadhar, Joshua, Hersey, Dronca, Joseph, Hille, Xue, Li, Kang, Ebbinghaus, Perrone, Wolchok Tags: Chemotherapy, CT Immunotherapy Source Type: research